ORNITHINE

OTHER NAME(S):

Chlorhydrate d'Ornithine, L-Ornithine, L-Ornithine HCl, L-Ornithine Hydrochloride, L-5-aminorvaline, L-2,5-diaminovaleric acid, Ornithine HCl, Ornitina.<br/><br/>

Overview

Overview Information

Ornithine is a chemical called an amino acid. It is made in the body. It can also be made in a laboratory. People use it as a medicine.

Ornithine is commonly used by mouth for improving athletic performance. It is also used for weight loss, wound healing, and to increase sleep quality. But there is limited scientific research to support these other uses.

Don't confuse ornithine with ornithine alpha-ketoglutarate (OKG) or L-Ornithine-L-Aspartate.

How does it work?

It's not known how ornithine might work for medical uses. However, ornithine might help to increase levels of the amino acid, arginine. It might also increase levels of hormones that increase muscle size.

Uses

Uses & Effectiveness?

Possibly Effective for

  • Athletic performance. Taking ornithine by mouth might reduce fatigue and improve measures of athletic performance such as speed, strength, and power in some people. Also, taking ornithine in combination with arginine seems to improve strength and power in male weightlifters.

Insufficient Evidence for

  • Sleep quality. Taking ornithine by mouth might improve sleep quality or sleep length in healthy adults.
  • Weight loss.
  • Wound healing.
  • Other conditions.
More evidence is needed to rate the effectiveness of ornithine for these uses.

Side Effects

Side Effects & Safety

Ornithine is POSSIBLY SAFE when taken by mouth at doses of up to 500 mg daily for up to 8 weeks.

Special Precautions & Warnings:

Pregnancy and breast-feeding: There is not enough reliable information about the safety of taking ornithine if you are pregnant or breast-feeding. Stay on the safe side and avoid use.

Interactions

Interactions?

We currently have no information for ORNITHINE Interactions.

Dosing

Dosing

The following doses have been studied in scientific research:

ADULTS

BY MOUTH:

  • For athletic performance: 1 gram twice/day for 7 days, then 3 grams with breakfast and lunch prior to exercise or athletic event. A single dose of ornithine hydrochloride 0.1 gram/kg taken prior to exercise or athletic event has also been used. Some people may take 1 gram of ornithine with 1 gram of arginine per day.

View References

REFERENCES:

  • Lang I, Feher J Gogl A Varga L Varga L Pronai L Werling K. Ammonia-lowering effect of ornithine-aspartate infusion in cirrhotic patients with hepatic encephalopathy. Gut. 1994;35 (Suppl 4):A158.
  • Liu, C. P. and Yu, Z. J. [Study on L-Ornithine-L-Aspartate in the treatment of acute-on-chronic liver failure]. Zhonghua Gan Zang.Bing.Za Zhi. 2011;19(1):63-64. View abstract.
  • Melzer, H., Weber, D., and Wotzka, R. [On the therapy of liver diseases with ornithine aspartate]. Med.Klin. 1969;64(35):1541-1544. View abstract.
  • Mittal, V. V., Sharma, B. C., Sharma, P., and Sarin, S. K. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur.J.Gastroenterol.Hepatol. 2011;23(8):725-732. View abstract.
  • Ndraha, S., Hasan, I., and Simadibrata, M. The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition. Acta Med.Indones. 2011;43(1):18-22. View abstract.
  • Neki NS, Batra KS Talwar AS Sharma RK Sharma N Multani LS. A comparative study of silymarin and l-ornithine - l-asparate in the treatment of viral hepatitis. The Journal of the Association of Physicians of India. 2000;
  • Nilius R, Kirecheis G. Improvement of hepatic encephalopathy (HE) in cirrhotic patients by treatment with L-ornithine-L-aspartate (OA) infusion concentrate Results of a placebo-controlled, double-blind clinical trial. Journal of Hepatology. 1992;16 (Supp 1)(S39)
  • O'Rourke, D. J., Ryan, S., Salomons, G., Jakobs, C., Monavari, A., and King, M. D. Guanidinoacetate methyltransferase (GAMT) deficiency: late onset of movement disorder and preserved expressive language. Dev.Med.Child Neurol. 2009;51(5):404-407. View abstract.
  • Ong, J. P., Oehler, G., Kruger-Jansen, C., Lambert-Baumann, J., and Younossi, Z. M. Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study. Clin.Drug Investig. 2011;31(4):213-220. View abstract.
  • Payne-James J, Grimble G Cahill E Silk D. Jejunal absorption of ornithine in man. Clin-Nutr. 1988;7:18.
  • Poo JL, Gongora J Sanchez-Avila JF Aguilar-Castillo S Garcia Ramos G Fernandez-Zertuche M Rodriguez-Fragoso L Uribe M. Efficacy and safety of L-ornithine-L-aspartate (LOLA) administration. Open label randomized controlled trial versus lactulose in cirrhotic patients with hyperammonemic hepatic encephalopathy. Journal of Hepatology. 2007;46(4 (Suppl 1)):S36.
  • Poo, J. L., Gongora, J., Sanchez-Avila, F., Aguilar-Castillo, S., Garcia-Ramos, G., Fernandez-Zertuche, M., Rodriguez-Fragoso, L., and Uribe, M. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann.Hepatol. 2006;5(4):281-288. View abstract.
  • Rees C, Oppong K Al-Mardini H Hudson M Rose J Record C. The effect of L-Ornithine-L-asparate on tips patients undergoing glutamine challenge. European Journal of Gastroenterology & Hepatology. 1996;8(Suppl 5):A1.
  • Rees CJ, Oppong K Al-Mardini H Hudson M Rose J. The effect of L-ornithine-L-aspartate on TIPS patients undergoing glutamine challenge. Advances in hepatic encephalopathy & metabolism in liver disease. 1997;56:407-411.
  • Reynolds N, Downie S Smith K Kircheis G Rennie MJ. Treatment with L-ornithine-L-aspartate (LOLA) infusion restores muscle protein synthesis responsiveness to feeding in patients with cirrhosis. Journal of Hepatology. 1999;30(Suppl 1):65.
  • Schmid M, Konig F Ferenci P Gang A Peck-Radosavljevic M. Prospective randomized pilot trial of i.v. l-ornithine-l-aspartate (LOLA) vs. placebo on postural control in patients with cirrhosis. Journal of Hepatology. 2008;48(Suppl 2):S12.
  • Sikorska, H., Cianciara, J., and Wiercinska-Drapalo, A. [Physiological functions of L-ornithine and L-aspartate in the body and the efficacy of administration of L-ornithine-L-aspartate in conditions of relative deficiency]. Pol.Merkur Lekarski. 2010;28(168):490-495. View abstract.
  • Simell, O. and Perheentupa, J. Renal handling of diamino acids in lysinuric protein intolerance. J.Clin.Invest 1974;54(1):9-17. View abstract.
  • Soarez, P. C., Oliveira, A. C., Padovan, J., Parise, E. R., and Ferraz, M. B. A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment. Arq Gastroenterol. 2009;46(3):241-247. View abstract.
  • Staedt, U., Leweling, H., Gladisch, R., Kortsik, C., Hagmuller, E., and Holm, E. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J.Hepatol. 1993;19(3):424-430. View abstract.
  • Stauch S, Rosch W. Effects of L-ornithine-L-aspartate granulate on hyperammonemia in cirrhotic patients with hepatic encephalopathy (HE). A placebo-controlled double-blind study. Zeitschrift fur Gastroenterologie. 1992;30(4):300-301.
  • Stauch, S., Kircheis, G., Adler, G., Beckh, K., Ditschuneit, H., Gortelmeyer, R., Hendricks, R., Heuser, A., Karoff, C., Malfertheiner, P., Mayer, D., Rosch, W., and Steffens, J. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J.Hepatol. 1998;28(5):856-864. View abstract.
  • Stechmiller, J. K., Childress, B., and Cowan, L. Arginine supplementation and wound healing. Nutr.Clin.Pract. 2005;20(1):52-61. View abstract.
  • Sugino, T., Shirai, T., Kajimoto, Y., and Kajimoto, O. L-ornithine supplementation attenuates physical fatigue in healthy volunteers by modulating lipid and amino acid metabolism. Nutr.Res. 2008;28(11):738-743. View abstract.
  • Tsai B-H, Lee N-Y. Effect of arginine and ornithine supplementation on weightlifters' fat free mass and anaerobic power. Nutritional Sciences Journal. 1997;22(4):373-383.
  • Yuan, Wenming. Li Jing. Xu Lin. Zhang Mingming. Lu Zhenchan. Feng Shejun. Wang Ling. L-ornithine-L-aspartate for hepatic encephalopathy. Cochrane Hepato-Biliary Group Cochrane Database of Systematic Reviews. 2009;
  • Bucci LR, Hickson JF Jr, Wolinsky I, Pivarnik JM. Ornithine supplementation and insulin release in bodybuilders. Int J Sport Nutr 1992;2:287-91. View abstract.
  • Fogelholm GM, Naveri HK, Kiilavuori KT, Harkonen MH. Low-dose amino acid supplementation: no effects on serum human growth hormone and insulin in male weightlifters. Int J Sport Nutr 1993;3:290-7. View abstract.
  • Hol JW, van Lier F, Valk M, Klimek M, Stolker RJ, Fekkes D. Effect of major and minor surgery on plasma levls of arginine, citrulline, nitric oxide metabolites, and ornithine in humans. Ann Surg 2013;258(6):1072-8. View abstract.
  • Horiuchi M, Kanesada H, Miyata T, et al. Ornithine ingestion improved sleep disturbances but was not associated with correction of blood tryptophan ratio in Japanese Antarctica expedition members during summer. Nutr Res 2013;33(7):557-64. View abstract.
  • Manufacturer: Twinlab. Ronkonkoma, NY.
  • Miyake M, Kirisako T, Kokubo T, et al. Randomised controlled trial of the effects of L-ornithine on stress markers and sleep quality in healthy workers. Nutr J 2014;13:53. View abstract.
  • Rees C, Oppong K, Mardini H, et al. Effect of L-Ornithine-L-Aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Gut 2000;47:571-4.. View abstract.
  • Schmid M, Peck-Radosavljevic M König F Mittermaier C Gangl A Ferenci P. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis. Liver Int. 2010;30(4):574-582. View abstract.
  • Zajac A, Poprzecki S, Zebrowska A, Chalimoniuk M, Langfort J. Arginine and ornithine supplementation increases growth hormone and insulin-like growth factor-1 serum levels after heavy-resistance exercise in strength-trained athletes. J Strength Cond Res 2010;24(4):1082-90. View abstract.
  • Kuttig H. Ornithine aspartate improves toleration of large-volume abdominal radiotherapy. Cochrane Central Register of Controlled TrialsTHERAPIEWOCHE. 1983;33(25):3495-3511.
  • Abid S, Mumtaz K Abbas Z Hamid S Jafri N Ali Shah H Jafri W. Efficacy of infusion of L-ornithine L-aspartate in cirrhotic patients with portosystemic encephalopathy: a placebo controlled study. Journal of Hepatology. 2005;42 (Supp 2):84.
  • Acharya, S. K., Bhatia, V., Sreenivas, V., Khanal, S., and Panda, S. K. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology 2009;136(7):2159-2168. View abstract.
  • Ahmad, I., Khan, A. A., Alam, A., Dilshad, A., Butt, A. K., Shafqat, F., Malik, K., and Sarwar, S. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy. J.Coll.Physicians Surg.Pak. 2008;18(11):684-687. View abstract.
  • Anon. Therapeutic efficacy of oral L-ornithine-L-aspartate on minimal encephalopathy. EBM Reviews - Cochrane Central Register of Controlled Trials. 2008;ClinicalTrials.gov
  • Chen, M. F., Li, R. C., Chen, C. H., and Gao, X. C. [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy]. Di Yi.Jun.Yi.Da.Xue.Xue.Bao. 2005;25(6):718-9, 722. View abstract.
  • Cynober, L., Coudray-Lucas, C., De Bandt, J. P., Guechot, J., Aussel, C., Salvucci, M., and Giboudeau, J. Action of ornithine alpha-ketoglutarate, ornithine hydrochloride, and calcium alpha-ketoglutarate on plasma amino acid and hormonal patterns in healthy subjects. J.Am.Coll.Nutr. 1990;9(1):2-12. View abstract.
  • Demura, S., Morishita, K., Yamada, T., Yamaji, S., and Komatsu, M. Effect of L-ornithine hydrochloride ingestion on intermittent maximal anaerobic cycle ergometer performance and fatigue recovery after exercise. Eur.J.Appl.Physiol 2011;111(11):2837-2843. View abstract.
  • Demura, S., Yamada, T., Yamaji, S., Komatsu, M., and Morishita, K. The effect of L-ornithine hydrochloride ingestion on performance during incremental exhaustive ergometer bicycle exercise and ammonia metabolism during and after exercise. Eur.J.Clin.Nutr. 2010;64(10):1166-1171. View abstract.
  • Elam, R. P. Morphological changes in adult males from resistance exercise and amino acid supplementation. J.Sports Med.Phys.Fitness 1988;28(1):35-39. View abstract.
  • Elam, R. P., Hardin, D. H., Sutton, R. A., and Hagen, L. Effects of arginine and ornithine on strength, lean body mass and urinary hydroxyproline in adult males. J Sports Med.Phys.Fitness 1989;29(1):52-56. View abstract.
  • Feher J, Lang I Gogl A Varga L Varga L Tompos G Pronai L. Effect of ornithine-aspartate infusion on elevated serum ammonia concentration in cirrhotic patients - Results of a randomized, placebo-controlled double-blind multicentre trial. Medical Science Monitor. 1997;3(5):669-673.
  • Fleig WE, Kircheis G Spengler U Zeuzem ST Gortelmeyer. Placebo-controlled, double-blind evaluation of L-ornithine-L-aspartate (LOLA) granules in patients with cirrhosis and subclinical (SHE) or mild overt hepatic encephalopathy (HE). Journal of Hepatology. 1999;30(1):65.
  • Hartung, H. D. [Amino acids prevent hepatic encephalopathy. Ornithine-aspartate in hyperammonemia--results of a study]. Fortschr.Med. 3-15-1989;107(8):56. View abstract.
  • Holm E, Hess Y Leweling H Barth H-O Hagmuller E. Ornithine aspartate (OA) promotes amino acid (AA) retention in the peripheral tissues of patients with liver cirrhosis A double-blind randomized crossover study. Journal of Parenteral and Enteral Nutrition. 2000;15(1):368.
  • Hong Y, Yang ZB Wang YF. Clinical Control Study of L-ornithine-L-aspartate in the Treatment of Subclinical Hepatic Encephalopathy. West China Medical Journal. 2003;18(4):509-510.
  • Hunold, W. [Clinical experiences in liver diseases (specially in patients with fatty liver due to alcoholism and food poisoning) under monotherapy with ornithine aspartate]. Z.Allgemeinmed. 4-10-1973;49(10):469-472. View abstract.
  • Jiang, Q., Jiang, X. H., Zheng, M. H., and Chen, Y. P. L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis. J.Gastroenterol.Hepatol. 2009;24(1):9-14. View abstract.
  • Kawada H. Clinical efficacy of ornithine aspartate for chronic liver injury accompanied by hyperammonemia: a double-blind study. The Japanese Journal of Clinical and Experimental Medicine. 1979;56(4):1294-1306.
  • Kircheis G, Metz M Frey S Seiller E. Correlation between pharmacokinetic aspects and clinical efficacy of L-ornithine-L-aspartate (OA): results of randomized, controlled clinical trials. Journal of Hepatology. 1996;25 (Suppl 1):S131.
  • Kircheis, G., Nilius, R., Held, C., Berndt, H., Buchner, M., Gortelmeyer, R., Hendricks, R., Kruger, B., Kuklinski, B., Meister, H., Otto, H. J., Rink, C., Rosch, W., and Stauch, S. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997;25(6):1351-1360. View abstract.

Vitamins Survey

Have you ever purchased ORNITHINE?

Did you or will you purchase this product in-store or online?

Where did you or where do you plan to purchase this product?

Where did you or where do you plan to purchase this product?

What factors influenced or will influence your purchase? (check all that apply)

Vitamins Survey

Where did you or where do you plan to purchase this product?

Do you buy vitamins online or instore?

What factors are most important to you? (check all that apply)

This survey is being conducted by the WebMD marketing sciences department.Read More

More Resources for ORNITHINE

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2018.